NCT06092047 2025-05-16
UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Recruiting
Clinical Trials
9 trialsNCT06756321 2025-01-03
A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
Affiliated Hospital of Nantong University
Phase EARLY_PHASE1 Recruiting
NCT06696833 2024-11-20
Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University
Phase EARLY_PHASE1 Recruiting
NCT06532643 2024-09-19
Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma
Shanghai First Song Biotechnology Co., LTD
Phase EARLY_PHASE1 Recruiting
NCT06224049 2024-03-12
GI-hNeoT-01
BGI, China
Phase EARLY_PHASE1 Recruiting
NCT04264078 2021-06-28
Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies
Xinqiao Hospital of Chongqing
Phase EARLY_PHASE1 Unknown
NCT04626726 2020-11-13
Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation
Hebei Senlang Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04626765 2020-11-13
CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia
Hebei Senlang Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04264039 2020-02-11
Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies
Xinqiao Hospital of Chongqing
Phase EARLY_PHASE1 Unknown